HICKSVILLE, NY , Feb. 22, 2018 (GLOBE NEWSWIRE) -- Canbiola, Inc. (OTC PINK: CANB) in its continuing effort to attract and partner with industry experts in the Global Health and Wellness field is proud to announced today that Dr. Matt Ferenc is joining the Medical Advisory Board and has also signed on as a Distributor. Dr. Ferenc stated, “I am honored and excited to join the Medical Advisory Board at Canbiola. Canbiola’s CBD products are at the forefront of emerging treatment protocols in a wide range of disease states including chronic pain, neurologic disorders, psychiatric disabilities and potential cancer treatments. The research and dedication of Canbiola to further our understanding of the medical benefits of CBD will catapult wellness and disease prevention exponentially.”
Marco Alfonsi, Canbiola CEO, stated, “We are continuing to execute our plan to strengthen not only our Medical Advisory Board but also our distribution network. With the addition of Dr. Ferenc, we have added the 7th doctor to our Medical Advisory Board and believe this addition will enhance our product development in new areas and further grow sales and geographically expand our client base.”
Dr. Ferenc joins a growing all-star medical advisory team that already has the following members:
About Dr. Maciej Ferenc, DO. / Medical Advisor
Dr. Ferenc is a practicing Emergency Medicine Physician with 16 years of experience working in a Level One (I) Trauma Center, treating all medical emergencies and is also a psychiatric accepting facility. Dr. Ferenc is well versed in treating emergencies ranging from trauma, strokes, acute myocardial infarctions and other emergent medical emergencies. Many of these emergent conditions he classifies as man-made. These man-made conditions include certain forms of cancer, Type II diabetes, hypertensive disorders, and several psychiatric conditions. Over the course of the last 16 years, Dr. Ferenc has realized that man-made diseases are responsible for most visits to the emergency room and has taken the initiative to learn the true causes of these diseases. In this journey, he has found that there are potential remedies which can help alleviate many of the conditions that are presented by his patients. In his book, “Dr. Matt’s Plan, Living Longer and Healthier”, he details several of these modalities including CBD. He continues to explore new treatment modalities utilizing CBD and other non-pharmaceutical agents in the treatment of man-made diseases and chronic conditions.
Certifications and Training:
· Medical School: University of Medicine and Dentistry of NJ, SOM 1998
· American Board of Anti-Aging and Regenerative Medicine, 2008
· Assistant Clinical Professor for NOVA and FIU
· Practicing Emergency Medicine and Trauma since 2002
· Assistant Medical Director of EM, BHIP
Member of American College of Osteopathic Emergency Physicians
Member of American Osteopathic Association
About Canbiola, Inc.
Canbiola, Inc. is a public company trading under symbol CANB.
Canbiola, Inc. is a US Company embarking in the sale of a variety of Cannabidiol (CBD) based products. Canbiola is in the process of developing its own line of proprietary products as well as seeking synergistic value through acquisitions in the CBD and the medical cannabis industry. Cannabis is currently federally illegal and has legalized for medical purposes in some form in a limited number of states. The company has already launched several products found at www.canbiola.com.
The company also owns two technological solutions, WRAPmail (US Patent 8,572,275), which turns traditional email into a powerful marketing and branding tool, as well Prosperity Systems and the Bullseye platform of document management and compliance targeted at broker-dealers, public companies, and governmental agencies providing a flawless all-in-one solution for document management, retention and compliance.
Forward-looking statements and risks and uncertainties Matters discussed in this press release contain forward-looking statements. The words “anticipate,” “believe,” “estimate,” “may,” “intend,” “expect,” and similar expressions identify such forward-looking statements. Expected, actual results, performance, or achievements could differ materially from those contemplated, expressed, or implied by the forward-looking statements contained herein. Forward-looking statements are subject to a number of risks and uncertainties, including but not limited to, risks and uncertainties associated with, among other things, the impact of economic, competitive, and other factors affecting our operations, markets, products, and performance. The matters discussed herein should not be construed in any way, shape or manner of our future financial condition or stock price.